View More Recent Stories

Oct 8, 2024 10:00AM Baird Reiterates Outperform Rating on Soleno Therapeutics Inc. (SLNO)
Oct 8, 2024 09:17AM Stifel Reiterates Buy Rating on Soleno Therapeutics Inc. (SLNO)
Oct 8, 2024 09:14AM Oppenheimer Reiterates Outperform Rating on Soleno Therapeutics Inc. (SLNO)
Oct 8, 2024 08:31AM Soleno Therapeutics (SLNO) Announces Regulatory Update on DCCR Extended-Release Tablets to Treat Prader-Willi Syndrome
Sep 30, 2024 04:43PM Soleno Therapeutics Inc. (SLNO) PT Raised to $74 at Stifel
Sep 27, 2024 08:38AM Piper Sandler Reiterates Overweight Rating on Soleno Therapeutics Inc. (SLNO)
Sep 7, 2024 08:00PM Here's the list of biotech stocks that have key data catalysts in 2025
Sep 3, 2024 06:32AM H.C. Wainwright Starts Soleno Therapeutics Inc. (SLNO) at Buy
Aug 27, 2024 11:42AM Stifel Reiterates Buy Rating on Soleno Therapeutics Inc. (SLNO)
Aug 27, 2024 11:37AM Oppenheimer Reiterates Outperform Rating on Soleno Therapeutics Inc. (SLNO)
Aug 27, 2024 08:08AM Soleno Therapeutics (SLNO) Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome
Aug 22, 2024 06:58AM Piper Sandler Reiterates Overweight Rating on Soleno Therapeutics Inc. (SLNO)
Aug 15, 2024 08:01AM Soleno Therapeutics (SLNO) Announces Board Changes
Aug 7, 2024 04:42PM Soleno Therapeutics, Inc. (SLNO) Tops Q2 EPS by 2c
Jun 28, 2024 08:01AM Soleno Therapeutics (SLNO) Announces Submission of NDA to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome
View More Recent Stories